Literature DB >> 17265470

Effect of body temperature on chondroitinase ABC's ability to cleave chondroitin sulfate glycosaminoglycans.

Nicole J Tester1, Anna H Plaas, Dena R Howland.   

Abstract

Chondroitinase ABC (Ch'ase ABC) is a bacterial lyase that degrades chondroitin sulfate (CS), dermatan sulfate, and hyaluronan glycosaminoglycans (GAGs). This enzyme has received significant attention as a potential therapy for promoting central nervous system and peripheral nervous system repair based on its degradation of CS GAGs. Determination of the stability of Ch'ase ABC activity at temperatures equivalent to normal (37 degrees C) and elevated (39 degrees C) body temperatures is important for optimizing its clinical usage. We report here data obtained from examining enzymatic activity at these temperatures across nine lots of commercially available protease-free Ch'ase ABC. CS GAG degrading activity was assayed by using 1) immunohistochemical detection of unsaturated disaccharide stubs generated by digestion of proteoglycans in tissue sections and 2) fluorophore-assisted carbohydrate electrophoresis (FACE) and/or high-performance liquid chromatography (HPLC) to separate and quantify unsaturated disaccharide digestion products. Our results indicate that there is a significant effect of lot and time on enzymatic thermostability. Average enzymatic activity is significantly decreased at 1 and 3 days at 39 degrees C and 37 degrees C, respectively. Furthermore, the average activity seen after 1 day was significantly different between the two temperatures. Addition of bovine serum albumin as a stabilizer significantly preserved enzymatic activity at 1 day, but not 3 days, at 39 degrees C. These results show that the CS GAG degrading activity of Ch'ase ABC is significantly decreased with incubation at body temperature over time and that all lots do not show equal thermostability. These findings are important for the design and interpretation of experimental and potential clinical studies involving Ch'ase ABC. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17265470     DOI: 10.1002/jnr.21199

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  38 in total

Review 1.  Biomaterial Approaches to Modulate Reactive Astroglial Response.

Authors:  Jonathan M Zuidema; Ryan J Gilbert; Manoj K Gottipati
Journal:  Cells Tissues Organs       Date:  2018-12-05       Impact factor: 2.481

2.  Chondroitinase ABC promotes recovery of adaptive limb movements and enhances axonal growth caudal to a spinal hemisection.

Authors:  Stephanie C Jefferson; Nicole J Tester; Dena R Howland
Journal:  J Neurosci       Date:  2011-04-13       Impact factor: 6.167

3.  Intraspinal microinjection of chondroitinase ABC following injury promotes axonal regeneration out of a peripheral nerve graft bridge.

Authors:  Veronica J Tom; John D Houlé
Journal:  Exp Neurol       Date:  2008-02-14       Impact factor: 5.330

Review 4.  Regenerative therapies for central nervous system diseases: a biomaterials approach.

Authors:  Roger Y Tam; Tobias Fuehrmann; Nikolaos Mitrousis; Molly S Shoichet
Journal:  Neuropsychopharmacology       Date:  2013-09-04       Impact factor: 7.853

5.  Feasible stabilization of chondroitinase abc enables reduced astrogliosis in a chronic model of spinal cord injury.

Authors:  Andrea Raspa; Edoardo Bolla; Claudia Cuscona; Fabrizio Gelain
Journal:  CNS Neurosci Ther       Date:  2018-05-31       Impact factor: 5.243

6.  Sustained delivery of thermostabilized chABC enhances axonal sprouting and functional recovery after spinal cord injury.

Authors:  Hyunjung Lee; Robert J McKeon; Ravi V Bellamkonda
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-02       Impact factor: 11.205

Review 7.  Recent advances in nanotherapeutic strategies for spinal cord injury repair.

Authors:  Young Hye Song; Nikunj K Agrawal; Jonathan M Griffin; Christine E Schmidt
Journal:  Adv Drug Deliv Rev       Date:  2018-12-22       Impact factor: 15.470

8.  Gene delivery to overcome astrocyte inhibition of axonal growth: an in vitro model of the glial scar.

Authors:  Hannah M Tuinstra; Melissa M Ducommun; William E Briley; Lonnie D Shea
Journal:  Biotechnol Bioeng       Date:  2012-11-01       Impact factor: 4.530

Review 9.  Rewiring the spinal cord: Direct and indirect strategies.

Authors:  Maria Teresa Dell'Anno; Stephen M Strittmatter
Journal:  Neurosci Lett       Date:  2016-12-19       Impact factor: 3.046

Review 10.  Translational spinal cord injury research: preclinical guidelines and challenges.

Authors:  Paul J Reier; Michael A Lane; Edward D Hall; Y D Teng; Dena R Howland
Journal:  Handb Clin Neurol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.